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SHORT-TERM OUTCOME OF MASSIVE  
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SUMMARY – Massive pulmonary hemorrhage (MPH) in neonates is a severe condition fol-
lowed by many complications and associated with a high mortality rate. The aim of this study was to 
present the incidence, possible risk factors, and short-term outcome of neonatal MPH in Tuzla Can-
ton. We retrospectively analyzed data on neonates with MPH from January 2015 to December 2017. 
On statistical analysis, standard methods of descriptive statistics were used. During the three-year 
study period, 16 neonates developed MPH, 5 (31.25%) male and 11 (68.75%) female. Their mean 
gestational age was 29.48±2.21 weeks and mean birth weight 1276.69±387.65 grams. Seven (43.75%) 
neonates survived and 9 (56.25%) died. Significant differences between the two outcome groups (sur-
vivors/died) were found in gestational age, birth weight, birth length, 5-minute Apgar score, and 
length of treatment at the Neonatal Intensive Care Unit. In Tuzla Canton, MPH occurred mainly in 
preterm neonates requiring mechanical ventilation, with the incidence of 1.91% of total premature 
births. The short-term outcome was uncertain, with a high mortality rate of 56.25%. Lower gesta-
tional age, lower birth weight, lower birth length and lower 5-minute Apgar score were confirmed as 
risk factors for poor short-term outcome.
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Introduction
Massive pulmonary hemorrhage (MPH) in neo-
nates is a severe condition that is characterized by the 
presence of hemorrhagic fluid in the trachea accompa-
nied by respiratory decompensation. The short-term 
outcome could be dramatic and uncertain, followed by 
many complications, and with a high mortality rate. 
The exact pathogenesis is not known yet, but there are 
many factors that can contribute and lead to the devel-
opment of MPH. Older papers have reported MPH in 
both preterm and full-term neonates, with a higher 
mortality rate in preterm infants, and usually related to 
perinatal asphyxia, surfactant deficiency, and some se-
rious illnesses1. Currently, it is more often described in 
preterm ventilated neonates, with different incidence 
reports1-3. Typical presentation is dramatic and rapid 
deterioration that starts with reddish foamy discharge 
in the endotracheal tube or mouth. It is followed by 
hypotonia, bradycardia, apnea, pallor, and increased 
need for oxygen. Chest x-rays are usually nonspecific, 
as it may appear as fluffy opacities, focal ground-glass 
opacities or complete white-out lungs in widespread 
MPH. There are still no proper recommendations for 
treatment4,5. Even though surfactant usage is men-
tioned as a precipitating factor for MPH develop-
ment1, various studies show that surfactant therapy 
should be suggested for treatment of this disorder6-8. 
Also reportedly maternal prophylaxis with antenatal 
glucocorticoids is associated with a reduced risk of 
pulmonary hemorrhage9. Regarding prognosis, there 
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are controversial data on further development; some 
studies showed no impact10, whereas others demon-
strated it to carry an increased risk of neurodevelop-
mental disorders11. Regarding short-term outcome, 
studies report a mortality rate of 40% to 60%2,8,10.
The aim of this study was to assess the incidence, 
possible risk factors, and short-term outcome of neo-
natal MPH in Tuzla Canton.
Patients and Methods
In a retrospective observational study, medical re-
cords of all neonates admitted to the Neonatal Inten-
sive Care Unit (NICU), Department of Pediatrics, 
Tuzla University Clinical Center, during a three-year 
period (from January 2015 to December 2017), a total 
of 604 patients were screened, and we reviewed records 
of the neonates with observed and treated MPH; fi-
nally, data on 16 neonates were included in the study.
Patients were evaluated for baseline characteristics, 
predisposing factors for MPH, accompanying disor-
ders, and mortality. We reviewed data on patient de-
mographics including gestational age, birth weight, 
gender, and Apgar scores at the 1st and 5th minute, type 
of delivery, possible premature rupture of membrane, 
postnatal age at the time of NICU admission, time to 
manifest MPH, and inborn-outborn status. Charac-
teristics of the neonates admitted with MPH (N=16) 
are shown in Table 1.
Previous lung health was analyzed through initial 
radiographic lung findings obtained before MPH de-
velopment. We analyzed laboratory, microbiological 
and radiological findings, therapeutic procedures, 
length of NICU stay, and outcome. The study was ap-
proved by the institutional review board (Ethics Com-
mittee). Statistical analysis was performed by use of 
standard methods of descriptive statistics. The signifi-
cance of differences between the groups was tested by 
parametric and nonparametric tests of significance and 
methods of linear correlation using statistical Arcus 
Quick Stat and Systat software.
Results
From January 2015 to the end of December 2017, 
there were 11,425 neonates including 10,588 full-term 
and 837 preterm (625 late preterm and 212 very pre-
term) in Tuzla Canton, with a 7.33% preterm birth 
rate. In total, 604 neonates were admitted to the 
NICU, including 237 term and 367 premature (172 
late premature and 195 very preterm), and 265 neo-
nates (215 premature and 50 term) required mechani-
cal ventilation. During the three-year study period, 16 
premature neonates developed MPH, yielding the in-
cidence of 1.91% of the total number of premature 
births, 4.35% of the total number of premature infants 
who were treated in the NICU and 7.44% of those 
requiring mechanical ventilation. According to gender 
distribution, there were 5 (31.25%) male and 11 
(68.75%) female infants.
Table 1. Clinical characteristics of neonates with massive 
pulmonary hemorrhage













(g) 1276.7±387.7 850.0 1970.0
Birth length 
(cm) 39.2±5.2 28.0 47.0
Gestational age 
(weeks) 29.4±2.2 27 34
Apgar score 
1stminute 4.75±2.5 1 8
Apgar score  







MV (days) 9.7±9 3 30
NICU length 
of stay (days) 25.1±26.1 2 83
χ±SD= mean ± standard deviation; MPH = massive pulmonary 
hemorrhage; MV = mechanical ventilation; NICU = neonatal in-
tensive care unit
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The mean gestational age was 29.48±2.21 weeks. 
All neonates with MPH were premature infants aged 
under 35 gestational weeks (GW). Two of them were 
moderate preterm (32-34 GW), 14 were very preterm 
(<32 GW), and 4 were extremely preterm (<28 GW). 
The mean birth weight was 1276.69±387.65 g. All of 
them were low birth weight (<2500 g), 12 (75%) were 
very low birth weight (<1500 g) and 4 were extremely 
low birth weight (<1000 g).
Among the 16 neonates with MPH, the most 
commonly associated diseases were respiratory distress 
syndrome, perinatal asphyxia, intracranial hemorrhage, 
pneumonia, and sepsis (Table 2). Baseline laboratory 
findings in the observed neonates are shown in Table 
3. Laboratory parameters of inflammatory markers 
and coagulation status in neonates with MPH did not 
show significant difference in comparison to those 
without MPH, and 6 of the 9 neonates with sepsis had 
microbiological confirmation of the diagnosis. The 
most commonly isolated pathogens were coagulase 
negative Staphylococcus, Enterococcus sp. and Acineto-
bacter. Previous lung condition recorded on chest radi-





Very preterm  
(<32 GW) n=14
Extremely preterm 
(<28 GW) n=4 Total (N=16)
Respiratory distress syndrome 
(hyposurfactosis) 2 14 4 16
Perinatal asphyxia 1 8 2 9
Intracranial hemorrhage mild  
to moderate 2 6 1 8
Intracranial hemorrhage moderate  
to severe - 8 3 8
Pneumonia 1 9 1 10
Atelectasis 1 9 2 10
Pneumothorax - 2 1 2
Sepsis 1 8 3 9
GW = gestational weeks
Table 3. Baseline laboratory findings in neonates  
with massive pulmonary hemorrhage
Parameter χ±SD Minimum Maximum
C-reactive protein (mg/L) 22.22±51.32 1.6 205.3
White blood cell count (x109/L) 8.29±3.92 2.6 15.4
Absolute neutrophil count 5838.5±4533.8 567 9108
Hematocrit (L/L) 0.524±0.1 0.37 0.72
Hemoglobin (g/L) 183.0±5.7 124.0 252.0
Erythrocytes (x1012/L) 4.7±0.9 3.8 6.8
Platelets (x109/L) 165.2±0.9 53 300
Prothrombin time (INR) 1.216250±0.14 1.0 1.4
Activated partial thromboplastin time 51.41±3.88 45.3 56.4
Thrombin time 23.25±2.3 20 28.5
Fibrinogen (g/L) 2.41±0.67 1.4 3.8
χ±SD = mean ± standard deviation; INR = International Normalized Ratio
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ography (chest x-ray) before the onset of MPH gener-
ally described moderate or severe degree of respiratory 
distress syndrome and pneumonia in 10 neonates, bi-
lateral in 7 of them. Chest radiography after MPH 
was described in survivors as progression of infiltration 
and atelectasis, unilateral or bilateral.
In all cases, the diagnosis was based on clinical 
manifestation of sudden appearance of bloody fluid 
from the mouth, nose, or endotracheal tube, with re-
lated worsening of the respiratory and cardiovascular 
function to the state of severe shock. Actually, in all 
cases, it was a very urgent state of life endangerment, 
which required urgent action for treatment and resus-
citation. Emergency treatment included standard re-
suscitation procedures (aspiration, re-intubation, air-
way cleaning procedures) with simultaneous adminis-
Table 5. Mortality (short-term outcome risk factors for massive pulmonary hemorrhage)
Parameter Survivors Non-survivors p value
n 7/16 9/16 0.4795
Male 2/7 3/9 0.8384
Gestational age (weeks), χ±SD (min-max) 30.57±2.37(27-34)
28.44±1.66
(26-31) 0.05
Birth weight (g), χ±SD (min-max) 1547.14±435.61(1000-1970)
1066.33±160.21
(850-1300) 0.0082
<1500 g 3/7 9/9 0.0088
>1500 g 4/7 0/9 0.0088
Birth length (cm), χ±SD (min-max) 43.0±1.41 (37-47) 36.22±3.46(32-44) 0.045
1-minute Apgar score, χ±SD (min-max) 6.0±4.58(3-7)
3.78±2.73
(1-8) 0.0714
5-minute Apgar score, χ±SD (min-max) 6.86±1.067(5-8)
4.78±2.11
(3-8) 0.0327
Postnatal age at MPH occurrence (days) 7.29±4.75(2-15)
7.44± 7.07
(2-25) 0.9601
Length of MV (days) 13.43±9.74(3-30)
6.78±7.64
(1-26) 0.1475
Surfactant replacement therapy 17/7 18/9 1.0
Length of NICU treatment (days) 47.43± 24.42(13 – 83)
7.78± 7.31
(2 – 26) 0.0004
χ±SD = mean ± standard deviation; MPH = massive pulmonary hemorrhage; MV = mechanical ventilation; NICU = Neonatal 
Intensive Care Unit
Table 4. Abnormal laboratory findings in neonates with massive pulmonary hemorrhage
Parameter Total, n Survivors Non-survivors p value
C-reactive protein <5 mg/L 10 5/7 5/9 0.5152
C-reactive protein >10 mg/L 6 2/7 4/9 0.7710
White blood cell count <6x109/L 7 4/7 3/9 0.3409
White blood cell count >13x109/L 5 3/7 2/9 0.3770
Hematocrit <0.45 4/16 2/7 2/9 0.7711
Hematocrit >0.65 2/16 1/7 1/9 0.8489
Platelets <150x109/L 8/16 2/7 6/9 0.1306
Coagulation disorders 4/16 2/7 2/9 0.7711
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tration of crystalloids, colloids, blood products and 
medications. Epinephrine via endotracheal route was 
applied in all cases, and in 4 cases a surfactant was ad-
ministered shortly after MPH onset. All patients re-
quired correction parameters on mechanical ventila-
tion and demanded reinforcing respiratory support. 
The length of mechanical ventilation was 3-30 (9.7±9) 
days and of NICU stay 3-84 (25.0±26.1) days.
In conclusion, as for the short-term outcome, 7 
(43.75%) MPH neonates survived, whereas 9 (56.25%) 
MPH neonates died. All perinatal risk factors were 
analyzed in the two groups of neonates with MPH 
divided according to outcome (survivors/died). There 
were no significant differences in baseline laboratory 
findings between the two groups of MPH neonates 
according to outcome (Table 4). Significant differenc-
es between the two groups were found in gestational 
age, birth weight, birth length, 5-minute Apgar score, 
and length of NICU treatment (Table 5). All these pa-
rameters were worse in the group of non-survivors, 
except for the length of NICU treatment, which was 
significantly longer in survivors.
Discussion
Massive pulmonary hemorrhage is a life-threaten-
ing condition that, according to current literature, 
complicates hospital course in 3%-5% of preterm in-
fants and generally occurs in 1-12 per 1000 live births, 
with the rate increasing to 50 per 1000 live births in 
the groups at risk such as prematurity and severe ill-
nesses1-3. In our region, we found the incidence of 
MPH to be 1.91% of total premature births, 4.35% of 
NICU treated preterm neonates, and 7.44% of those 
requiring mechanical ventilation. Gender distribution 
usually shows a slight predominance of female infants2, 
as also recorded in our study. As for gestational age, all 
neonates with MPH in our study were premature in-
fants, nearly all (87.5%) were very preterm neonates 
(<32 GW), and a quarter of all were extremely imma-
ture (<28 GW). Very similar results were obtained for 
the birth weight parameter because all MPH neonates 
in our study were low birth weight (<2500 g), nearly all 
(75%) were very low birth weight (<1500 g), and a 
quarter of all were extremely low birth weight (<1000 
g). In studies from the 1990s, MPH occurred in both 
preterm and full-term neonates, however, in preterm 
infants it developed later and was associated with a 
higher mortality rate than in full-term infants11,12. Re-
cent major studies have just highlighted lower gesta-
tional age and lower birth weight as the strongest risk 
factors for the development of MPH2,3.
The exact pathogenesis of MPH remains unknown, 
however, there are many factors that can contribute 
and lead to the development of MPH. It is related to 
perinatal asphyxia, surfactant deficiency, hypothermia, 
septicemia, pneumonia, coagulation disorders, con-
genital heart disease, maternal blood aspiration, intra-
venous administration of hyperosmolar solutions, and 
diffuse pulmonary embolism with drug micro-aggre-
gates1. In our study, the most commonly associated 
diseases in neonates with MPH were respiratory dis-
tress syndrome, perinatal asphyxia, intracranial hemor-
rhage, pneumonia and sepsis, which is consistent with 
literature data, possibly better with the older one11. Be-
cause most of the patients suffered from perinatal as-
phyxia, it was assumed that left ventricular failure with 
subsequent increase in pulmonary capillary pressure 
was one of the main precipitating factors. In their 
study, West et al.12 suggest that stress failure of pulmo-
nary capillaries due to alveolar overdistention and high 
pulmonary capillary pressure, which causes leakage of 
hemorrhagic edema fluid into air spaces, is one of the 
most likely mechanisms of MPH development. Pul-
monary hemorrhage occurs mainly in ventilated pre-
term infants with severe respiratory distress syndrome 
who have received surfactant therapy13. There is evi-
dence that surfactant impairs coagulation in vitro, and 
therefore it is seriously considered as a risk factor for 
pulmonary hemorrhage14. Some authors suggest that 
the use of a surfactant can lead to rapid lowering of 
intrapulmonary pressure and consequential increase in 
pulmonary blood flow by facilitating left to right 
shunting across patent ductus arteriosus (PDA), which 
can cause pulmonary hemorrhage6-8. We did not find 
significant differences in surfactant treatment between 
surviving neonates with MPH compared to those who 
did not survive. We did not find any significant differ-
ences in coagulation status either.
In emergencies such as life-threatening MPH, it is 
essential to have consistent recommendations for ef-
fective treatment, which unfortunately, has not been 
reached yet. Different approaches have been proposed 
including high airway pressures during mechani- 
cal ventilation, high frequency oscillation ventila- 
tion (HFOV), extracorporeal membrane oxygenation 
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(ECMO), administration of recombinant activated 
factor VII, and surfactant replacement therapy5-8. Cer-
tainly, it is very important how we treat respiratory 
failure. Mechanical ventilation in neonates is still a 
more complex area, the safety and successful applica-
tion of which requires good knowledge of pulmonary 
physiology and pathophysiology that is changing with 
age, and ventilation should be designed according to 
the age, lung disease characteristics and pathophysio-
logical process causing respiratory insufficiency. Cur-
rently, there are many options, strategies and modali-
ties, suggesting that we have not created an ideal mode 
yet, which would maximally respond to the needs of a 
child and expedite recovery with minimal complica-
tions15. MPH has been effectively treated with surfac-
tant instillation, even in those neonates who have al-
ready received this before6-8. Pandit et al.10 noted im-
provement of the oxygen index when they used a sur-
factant in 15 neonates with MPH. Amizuka et al.6 
used a surfactant in 26 of 27 neonates with MPH, with 
good response in 82% of cases at one hour after surfac-
tant administration. Grizelj et al.5 used activated factor 
VII to provide maximum activation of the coagulation 
system localized to the site of injury, and recommend 
it as a safe additional life-saving therapeutic option for 
neonates experiencing life-threatening MPH. Sury-
awanshi et al.8 promote treatment for neonatal MPH, 
almost identical to that in our institution, which in-
cludes epinephrine via endotracheal tube, avoiding 
unnecessary endotracheal suction, blood products, and 
correction of treatment for secondary respiratory dis-
tress syndrome by appropriate and best respiratory 
support, with or without repeat surfactant.
Prevention could be more effective than treatment. 
Could MPH be predicted or prevented, and could risk 
factors for poor short-term outcome be recognized 
earlier? Reportedly maternal prophylaxis with antena-
tal glucocorticoids is associated with a reduced risk of 
pulmonary hemorrhage9. We did not find significant 
differences in the maternal risk factors or use of ante-
natal corticosteroid prophylaxis between surviving 
neonates with MPH compared to those who did not 
survive. We did not find significant difference in base-
line laboratory findings either. Significant differences 
between the two groups were recorded in gestational 
age, birth weight, birth length, 5-minute Apgar score, 
and length of NICU treatment. Most studies report a 
similar mortality rate for MPH and similar risk factors 
for poor outcome, although in our study we did not 
find any significance regarding maternal risk factors, 
antenatal corticosteroid prophylaxis, or surfactant 
treatment. Usually, birth weight discordance is report-
ed as a risk factor for adverse perinatal outcomes16. It is 
interesting that in our research, the mean birth length 
was significantly lower in the group of non-survivors 
as compared to survivors. For comparison, there is al-
most no study that considered birth length at all. The 
length of NICU treatment was significantly longer in 
survivors (47.42±24.41 days) versus those with lethal 
outcome (7.45±7.07 days).
Conclusion
Because of its outstanding severity and high mor-
tality rates, neonatal MPH deserves great attention of 
all, and not only those who provide intensive care for 
premature neonates. In Tuzla Canton, MPH occurred 
mainly in preterm neonates and those requiring me-
chanical ventilation due to respiratory distress syn-
drome. The incidence of MPH was 1.91% of total pre-
mature births, 4.35% of NICU treated preterm neo-
nates, and 7.44% of those requiring mechanical venti-
lation. The short-term outcome was uncertain, i.e. 
favorable in 43.75% of survivors, while the mortality 
rate was high (56.25%). We did not find significant 
difference regarding maternal risk factors, antenatal 
corticosteroid prophylaxis, or surfactant treatment be-
tween surviving neonates with MPH and non-survi-
vors. Lower gestational age, lower birth weight, lower 
birth length, and lower 5-minute Apgar score were 
confirmed as the risk factors for poor short-term out-
come in neonates with MPH.
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Sažetak
RANI ISHOD MASIVNOG PLUĆNOG KRVARENJA KOD NEDONOŠČADI  
U TUZLANSKOM KANTONU
D. Hadžić, E. Zulić, S. Salkanović-Delibegović, Dž. Softić, Dž. Kovačević i D. Softić
Masivna plućna hemoragija (MPH) u novorođenčadi je teško stanje koje prati mnoštvo komplikacija i visoka stopa smrt-
nosti. Cilj ovoga istraživanja bio je utvrditi incidenciju, moguće čimbenike rizika i kratkoročni ishod neonatalne MPH u 
Tuzlanskom kantonu. Retrospektivno smo analizirali podatke o novorođenčadi s MPH od siječnja 2015. do prosinca 2017. 
godine. U statističkoj obradi primijenjene su standardne metode deskriptivne statistike.Tijekom promatranog trogodišnjeg 
razdoblja MPH se razvila u 16 novorođenčadi, 5 dječaka (31,25%) dječaka i 11 (68,75%) djevojčica. Srednja gestacijska dob 
bila je 29,48±2,21 tjedana, a srednja porođajna težina 1276,69±387,65 grama. Svih 16 bili su neonoščad niske porođajne 
težine od kojih je 7 (43,75%) preživjelo, a 9 (56,25%) umrlo. Značajne razlike među dvjema skupinama ishoda nađene su za 
gestacijsku dob, porođajnu težinu, porođajnu duljinu, Apgar indeks u petoj minuti i dužinu intenzivnog liječenja. U zaključ-
ku, u Tuzlanskom kantonu neonatalna MPH javljala se kod nedonoščadi koja su zahtijevala mehaničku ventilaciju, s inciden-
cijom od 1,91% od ukupnog broja prijevremeno rođenih. Kratkoročni ishod bio je neizvjestan, s visokom stopom smrtnosti 
od 56,25%. Kraća gestacijska dob, niža porođajna težina, niža porođajna duljina i niži Apgar indeks u petoj minuti potvrđeni 
su kao čimbenici rizika za loš kratkoročni ishod.
Ključne riječi: Masivno plućno krvarenje; Nedonošče; Kratkoročni ishod; Čimbenici rizika
